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HIV-1 tropismR5X4 HIV-1 has impaired utilization of CCR5 on primary CD4+ lymphocytes but the mechanisms respon-
sible are not well deﬁned. Using a panel of diverse R5X4 Envs we identiﬁed a spectrum of CCR5 use on CD4+
lymphocytes. Greater lymphocyte CCR5 use correlated with relative resistance to CCR5 mAbs and small
molecule antagonists. Increasing CCR5 expression on lymphocytes increased the proportion of entry
mediated by CCR5 for all R5X4 isolates except 89.6. In cell lines with regulated CCR5 expression, strains with
greater lymphocyte CCR5 use better exploited limiting levels of CCR5. Introduction of an R306S mutation in
the 89.6 V3 domain enhanced its utilization of CCR5 at low levels and switched its preference to CCR5 for
lymphocyte entry. Thus, the degree to which R5X4 HIV-1 use primary lymphocyte CCR5 is determined by
low CCR5 expression coupled with variations in the efﬁciency of Env–CCR5 interactions, which is in part
governed by V3 sequences.and Hamilton Walk, Philadel-
. Collman).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
HIV-1 coreceptor use is inﬂuenced by variation in the interactions
between the cellular and viral proteins required for entry into target
cells. Viral entry is preceded by a series of structural changes in the
viral envelope glycoprotein that begins with binding to CD4, followed
by conformational changes that result in coreceptor binding and
membrane fusion. CCR5 and CXCR4 are the principal coreceptors used
by HIV-1 in vivo. Viruses that use CCR5 (R5 variants) are responsible
for nearly all newly transmitted infections whereas strains that
use CXCR4 are excluded from transmission and/or establishment of
new infections; interestingly, this includes both those that use CXCR4
alone (X4 variants) and those that use CCR5 and CXCR4 (R5X4
variants) (Scarlatti et al., 1997; van't Wout et al., 1994). R5 strains also
predominate during the early and intermediate stages of disease,
however, in nearly half of individuals infected with subtype B, CXCR4-
using variants arise late in infection and are associated with a
precipitous decline in CD4 counts and more rapid disease progression
(Connor et al., 1997; Koot et al., 1993; Tersmette et al., 1989). Theearliest CXCR4-using viruses typically retain CCR5 use (R5X4
variants), while viruses that are restricted to CXCR4 (X4 variants)
may emerge later (Hu et al., 2000; van Rij et al., 2000).
The major targets of HIV-1 infection are CD4+ lymphocytes and
macrophages. Previous studies from our lab showed that prototype
R5X4 viruses infected monocyte-derived macrophages using CCR5
and CXCR4 (Yi et al., 1999). In CD4+ lymphocytes, however, CCR5-
mediated infection by R5X4 HIV-1 was severely impaired despite
effective CCR5 use on these cells by R5 viruses and, consequently,
R5X4 entry into CD4+ lymphocytes occurred almost exclusively
through CXCR4 (Yi et al., 2005). Pathogenesis by R5X4 viruses is also
linked to CXCR4 use in several models. Infection and depletion
of lymphocytes in human lymphoid tissue infected ex vivo by R5X4
HIV-1 are completely blocked by the CXCR4 antagonist AMD3100, and
infection of rhesus macaques with SIV/HIV (SHIV) chimeras carrying
R5X4 envelopes induces a disease course similar to infection by X4
SHIVs (Glushakova et al., 1999; Malkevitch et al., 2001; Nishimura
et al., 2004). Thus, CXCR4 is the principal entry path used by R5X4
viruses to infect CD4+ lymphocytes whereas CCR5 does not appear to
substantially contribute to T cell infection by these viruses.
In contrast to those data, other studies have suggested that
lymphocyte CCR5 can be used by some R5X4 strains (Ghezzi et al.,
2001; Gray et al., 2006). It is unclear what factors contribute to the
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R5X4 viruses are unable to effectively utilize CCR5 as a coreceptor to
infect CD4+ lymphocytes. Several studies have suggested that, in
general, R5X4 variants tend to differ from R5 strains in a number of
factors including their requirements for CCR5 expression levels and
the molecular anatomy of CCR5 interactions (Lu et al., 1997; Simmons
et al., 2000; Yi et al., 2005, 2003b). Furthermore, the emergence of
R5X4 variants in vivo has been associated with increased sensitivity to
CCR5 antagonists and reduced ability to infect cells expressing low
levels of CCR5 relative to earlier R5 variants (Coetzer et al., 2008).
Whether these factors regulate coreceptor utilization on primary
lymphocytes, and whether differences among R5X4 strains may exist,
is not known.
The goal of this study was to examine the diversity among R5X4
HIV-1 in the efﬁciency of CCR5 use on lymphocytes, and to identify the
mechanisms that regulate its utilization. To do this, we assembled a
diverse panel of R5X4 envelope clones, determined the extent to
which CCR5 contributed to CD4+ lymphocyte infection by pseudo-
type reporter viruses, and related CCR5 use on lymphocytes to several
measures of envelope–coreceptor interaction. Our ﬁndings suggest
that the use of lymphocyte CCR5 by R5X4 HIV-1 is associated with the
overall efﬁciency of interaction with CCR5. We also found that
increasing CCR5 expression on lymphocytes could overcome the
barrier to entry mediated by this coreceptor for most (but not all)
R5X4 viruses. Thus, inefﬁcient interactions with CCR5 coupled with
low CCR5 expression on CD4+ lymphocytes are responsible for re-
stricting CCR5-mediated infection of T cells by R5X4 HIV-1 isolates.
Results
A spectrum of restricted CCR5-mediated entry into CD4+ lymphocytes
exists among R5X4 viruses
In order to examine the diversity in primary cell coreceptor
utilization among R5X4 HIV-1, and facilitate the identiﬁcation of
factors that inﬂuence primary cell coreceptor use, we assembled a
panel of diverse R5X4 env clones derived from divergent sources to
study. Luciferase reporter viruses were generated that carried primary
isolate R5X4 HIV-1 envelope clones from three different infected
individuals (DR, C2, NR), using several individual Envs from within
each swarm (Gorry et al., 2002; Gray et al., 2006; Ray et al., 2007). WeFig. 1. Coreceptor use on U87 indicator cells by HIV-1 pseudotype viruses. U87 indicator c
luciferase reporter viruses pseudotyped with primary isolate R5X4 envelopes (C2, DR and NR
(Tybe) as controls. Three days later, infection levels were determined by measuring lucifer
represent means±standard error (SEM) for two experiments performed in triplicate.also studied three widely used prototype R5X4 clones (89.6, DH12
and R3A)which are also primary isolate-derived (Collman et al., 1992;
Meissner et al., 2004; Shibata et al., 1995), along with control R5 and
X4 Envs Bal and Tybe, respectively (Hwang et al., 1991; Yi et al.,
2003a). Of note, 89.6, DH12 and NR envswere derived from late-stage
AIDS patients (Collman et al., 1992; Ray et al., 2007; Shibata et al.,
1995), which is the most common situation in which these variants
are seen. R3A was an R5X4 isolate obtained at the time of
seroconversion from an individual infected via intravenous drug use
who exhibited rapid disease progression (Meissner et al., 2004; Yu et
al., 1998), whereas C2 and DR were isolated from two CCR5-null
individuals (Gray et al., 2006). Dual CCR5 and CXCR4 use for each
virus was conﬁrmed by infecting U87 cells that expressed CD4 and
either CCR5 or CXCR4 (Fig. 1).
In order to determine coreceptor use by these viruses on primary
lymphocytes, CD4+ T cells were infected in the absence or presence
of CCR5 or CXCR4 antagonists M657 and AMD3100, respectively
(Fig. 2). As expected, Bal was completely inhibited by the CCR5
antagonist M657 and Tybe by the CXCR4 antagonist AMD3100. When
CD4+ lymphocytes were infected with R5X4 pseudotypes, a different
pattern was evident. All R5X4 strains were markedly inhibited by
CXCR4 blockade, whereas CCR5 blocking had no detectable effect. For
all R5X4 strains, however, the addition of M657 to AMD3100 further
reduced entry levels (Fig. 2A). These results indicate that all R5X4
viruses tested entered CD4+ lymphocytes through both CXCR4 and
CCR5, but that infection through CCR5 was markedly less than that
through CXCR4, and played little, if any, additional role when both
coreceptors were available.
To quantitate the relative contribution of each coreceptor to
infection of CD4+ lymphocytes, the luciferase levels in the presence
of coreceptor antagonists were normalized to the total infection
capacity for each virus in untreated cells (Fig. 2B). Blocking CCR5
alone had no inhibitory effect on infection for any of the viruses.
However, CXCR4 blocking, when compared to dual coreceptor
blocking, revealed CCR5-mediated infection that ranged from ≤10%
for the three prototype strains and two of the DR primary isolate Envs,
to 50% of untreated levels for the C2-16 primary isolate Env. Thus,
CXCR4 is the predominant coreceptor used by R5X4 viruses to infect
CD4+ lymphocytes. However, some entry can be mediated by CCR5,
and that proportion varies between isolates indicating a spectrum of
lymphocyte CCR5 use.ells expressing only CD4, CD4 and CCR5, or CD4 and CXCR4 were infected with HIV-1
), prototype R5X4 envelopes (89.6, DH12 or R3A), and R5 (Bal or JRFL) or X4 envelopes
ase activity in cell lysates. The results are expressed in relative light units (RLUs) and
Fig. 2. CXCR4 is the principal coreceptor on PHA/IL-2 stimulated CD4+ lymphocytes for R5X4 HIV-1 primary and prototype strains. CD4+ T cells were stimulated with PHA for
3 days then treated for 1 h before infection with or without the CXCR4 blocker AMD3100 (5 µg/ml; “CCR5 pathway”), CCR5 blocker M657 (5 µM; “CXCR4 pathway”) or both
(“neither pathway”). Cells were then infected with HIV-1 luciferase reporter viruses in the continued presence of coreceptor blockers andmaintained with IL-2 (10 U/ml). Four days
post-infection, viral entry was determined by luciferase activity in cell lysates. Results shown for each virus are presented in RLUs (A) and as a percentage of the RLUs seen in the
absence of coreceptor blockers (B). Data are means±SEM of three experiments using lymphocytes from different donors, each done in duplicate.
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antagonists correlates with the capacity of R5X4 HIV-1 to use CCR5 for
lymphocyte infection
Previous studies comparing CCR5 use by R5 and R5X4 Envs have
suggested that R5X4 Envs appear to have a lower afﬁnity for CCR5
than do R5 Envs, are generally more sensitive to inhibition by CCR5
antagonists and are more affected by changes in the structure of CCR5
(Cormier et al., 2000; Doranz et al., 1997; Lu et al., 1997; Yi et al., 2005,
2003b). Since R5 strains by deﬁnition use CCR5 efﬁciently for
lymphocyte entry, our ﬁnding that R5X4 strains vary in their capacity
to infect primary lymphocytes through CCR5 raised the possibility
that these strains might also vary in their interaction with CCR5.
To examine the relationship between Env–coreceptor inter-
actions and lymphocyte CCR5 use, we took advantage of CCR5-
speciﬁc mAbs with well-characterized target epitopes (Blanpain
et al., 2002; Lee et al., 1999a). U87/CD4/CCR5 cells were infected inthe presence or absence of mAbs that target epitopes in the amino
terminus (N-terminal), the second extracellular loop (ECL2) or
multiple domains (MD) of CCR5, and entry inhibition was deter-
mined by normalizing infection levels to those of untreated cells. As
shown in Fig. 3A, both mAbs that targeted CCR5 ECL2 (45531 and
MC-1) inhibited entry by the R5X4 viruses. Infection levels were
reduced 15–70% by mAb 45531 and 30–90% by MC-1. Treatment
with 2D7, another ECL2-directed mAb, completely inhibited infec-
tion by all viruses, even at four-fold lower concentrations (data not
shown). Importantly, R5X4 Envs that were better able to use
lymphocyte CCR5 for entry were blocked less efﬁciently than those
viruses that used the pathway poorly, as shown by the signiﬁcant
correlation between lymphocyte CCR5 use and infection in the
presence of ECL2-directed mAbs 45531 and MC-1 (Fig. 3A). In con-
trast to the ECL2-targeted antibodies, multidomain and N-terminal
antibodies (45523 and CTC8, respectively) had marginal or no effect
on entry (data not shown).
Fig. 3. CCR5 use on CD4+ lymphocytes correlates with resistance to inhibition by ECL2-directed CCR5 mAbs and small molecule antagonists. U87/CD4/CCR5 cells were treated for
1 h with or without 10 µg/ml of CCR5-speciﬁc mAbs (A) or increasing concentrations of CCR5 antagonists M657 or Maraviroc (B), then infected with HIV-1 luciferase pseudotype
viruses in the continued presence of mAb or blocker. Three days later, infection was determined by luciferase activity in cell lysates and normalized to luciferase activity in untreated
cells. Each symbol represents an individual R5X4 virus, and results are presented as the proportion of total lymphocyte entry mediated by CCR5 (from Fig. 2B) on the X-axis versus
the percentage of U87/CD4/CCR5 infection resistant to inhibition by CCR5mAbs (A) or the EC50 values for the small molecule CCR5 antagonists (B) on the Y-axis. Data are means for
three experiments each carried out in duplicate.
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frequently used as probes to assess Env–coreceptor interactions. Sen-
sitivity to CCR5 blockers M657 and Maraviroc was determined by
infecting U87/CD4/CCR5 cells in the presence of increasing concen-
trations of inhibitor. Infection by all viruses was extinguished at the
highest concentrations of each antagonist (data not shown), but there
was variation in sensitivity to both M657 and Maraviroc, exempliﬁed
by differences in antagonist EC50 values among the R5X4 Envs
(Fig. 3B). M657 and Maraviroc EC50 values were lower for R5X4 Envs
with poor lymphocyte CCR5 use, compared to Envs such as C2-16
that are better able to use this coreceptor. Similar to inhibition by
ECL2-directed CCR5 mAbs, M657 and Maraviroc EC50 values cor-
related with lymphocyte CCR5 use. Concordant mAb and antagonist
results show a link between lymphocyte CCR5 use and sensitivity
to blocking among R5X4 HIV-1, and suggest that the variation in
CCR5-mediated infection of lymphocytes results at least in part from
differences among these strains in the efﬁciency of interactions with
the coreceptor.
CCR5 upregulation on CD4+ lymphocytes increases the proportion of
R5X4 HIV-1 entry mediated by CCR5
These data indicate that CCR5-mediated infection of CD4+
lymphocytes by many R5X4 HIV-1 is restricted (Fig. 2), yet all these
viruses can use this coreceptor to readily infect indicator cells such as
U87 CD4/CCR5 cells (Fig. 1). CCR5 on indicator cells is typically over-
expressed, however, while peripheral blood lymphocytes express
CCR5 at low density and on a minority of cells (Lee et al., 1999b; Wu
et al., 1997). We therefore sought to test whether low levels of CCR5expression were an obstacle to efﬁcient CCR5 use on CD4+ lym-
phocytes by R5X4 viruses, and how CCR5 expression levels regulated
pathway-speciﬁc R5X4 lymphocyte entry.
To address the role of CCR5 expression, CD4+ lymphocytes were
infected with HIV-1 luciferase pseudotype viruses immediately after
3 days of CD3/CD28 costimulation, or after 10 additional days of
culture with 300 U/ml of IL-2, which has been shown to upregulate
lymphocyte CCR5 (Creson et al., 1999; Yang et al., 2001). Infections
were performed in the presence or absence of CCR5 and CXCR4
antagonists to determine proportional use of each entry pathway, and
coreceptor expression was measured by FACS at the time of infection.
Following CD3/CD28 costimulation, ∼1% of CD4+ lymphocytes were
CCR5+ as determined by surface staining, whereas 20–40% had
detectable CCR5 after prolonged culture. In addition to the increase in
percentage of cells within the CCR5+ gate, the mean ﬂuorescence
intensity (MFI) of cells within the CCR5 gate increased as well
(approximately 2-fold). In contrast, the percentage of cells expressing
CXCR4 decreased to a modest degree but remained higher after
culture with IL-2 (50–70%).
As shown in Fig. 4A, CCR5 use by R5X4 HIV-1 was restricted in
day 3 CD3/CD28-stimulated CD4+ lymphocytes, with CXCR4 being
the predominant pathway used for entry. However, there was a
modest spectrum of CCR5 use similar to that seen in PHA-stimulated
lymphocytes (Fig. 2). In contrast, CCR5 upregulation following
10 days of IL-2 stimulation dramatically increased the proportion
of infection mediated by CCR5 for all R5X4 viruses tested, except
for 89.6 (Fig. 4B). Despite elevated CCR5 expression, CXCR4 remained
the predominant coreceptor used for infection of day 13 CD4+
lymphocytes by most R5X4 strains. Exceptions to this coreceptor
Fig. 4. CCR5 upregulation on CD4+ lymphocytes increases the proportion of R5X4 infection mediated by CCR5. CD4+ lymphocytes were CD3/CD28 costimulated for three days and
then infected with HIV-1 luciferase pseudotype viruses (A) or cultured with IL-2 for 10 additional days to upregulate CCR5 expression prior to infection (B). Infections were carried
out with or without AMD3100, M657 or both antagonists to block CXCR4 and/or CCR5. Four days later, infection was determined by luciferase activity in cell lysates. Entry was
normalized as a percentage of the RLUs seen in the absence of coreceptor blockers for each virus. Data are means±SEM of three experiments using lymphocytes from different
donors, each done in duplicate.
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which CCR5 consistently mediated an equal or greater proportion of
entry than did CXCR4 on CCR5-upregulated CD4+ T cells (Fig. 4B).
VSV-G pseudotypes, used as a control, showed no change in luciferase
expression from day 3 to day 13 cells (data not shown).
The percentage of CD4+ lymphocytes infected through each coreceptor
is modulated following CCR5 upregulation
In addition to total infection levels within the cultures, we also
aimed to deﬁne the contribution of each pathway to infection of
individual CD4+ T lymphocytes following CCR5 upregulation. CD4+
lymphocytes were cultured for 3 or 13 days as described above to
establish standard or high CCR5 expression conditions, respectively,
and then infected with HIV-1 Env pseudotype virions carrying a GFP
reporter gene. Infection-mediated GFP expression therefore enabled
per cell analysis of infection based on GFP expression as determined
by FACS. As with luciferase infection, addition of both CCR5 and CXCR4
antagonists completely blocked GFP expression (data not shown).As shown in Fig. 5A, CCR5-mediated entry into day 3 CD4+
lymphocytes resulted in a low percentage of GFP-positive infected
cells. This value ranged from barely detectable (DH12) to ∼5% (C2-16
and the R5 Env JRFL). While this result is concordant with the low
percentage of cells positive for CCR5 expression by FACS, it was
interesting to note that the fraction of GFP+ cells for C2-16 and JRFL
often exceeded the proportion that was CCR5+ by FACS. Entry by
these viruses was clearly mediated by CCR5, however, since infection
was blocked by M657 or Maraviroc (data not shown). This ﬁnding
indicates that susceptibility to infection by efﬁcient CCR5-using Envs
can be a more sensitive indicator of CCR5 expression than immu-
nostaining, and thus these isolates can use CCR5 at levels that are
below the threshold of detection by FACS. Furthermore, the fact that
some strains can exploit CCR5 to infect what appear to be CCR5-
negative CD4+T cells by FACS indicates that, following upregulation,
the apparent increases in percentage of CCR5+ cells also reﬂect
increased CCR5 expression levels by cells that are initially CCR5-
positive but at a level below the threshold detectable by ﬂow
cytometry.
Fig. 5. Stimulation-dependent changes in coreceptor expression affect the percentage
of CD4+ lymphocytes infected via each pathway. CD4+ lymphocytes were infected
with HIV-1 GFP pseudotype viruses after 3 days of CD3/CD28 costimulation or
following an additional 10 days of culture with IL-2 to upregulate CCR5. Cells were
incubated with coreceptor antagonists for 1 h prior to and throughout the infection to
deﬁne the pathway of entry. CCR5 and CXCR4 expression were analyzed by FACS on the
day of infection, and four days later, infected cells were determined by FACS analysis
for GFP expression. Data indicate the percentage of GFP+ cells infected through
CCR5 (A) or CXCR4 (B) at day 3 and day 13 after isolation, and are representative of
three independent experiments using cells from different donors. The percentage of
cells expressing CCR5 (A) and CXCR4 (B) at the time of infection is indicated by an
asterisk (*).
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culture in IL-2 (Fig. 5A, right), the percentage of GFP+ cells infected
through CCR5 increased dramatically for the R5 isolate JRFL. Similarly,
the percentage of GFP+ cells infected through CCR5 also increased
for R5X4 viruses following CCR5 upregulation, although these per-
centages remained less than that for JRFL. Infection with VSV-G
pseudotypes, used as a control for possible effects independent of
coreceptor-mediated entry, showed no change in infection (54±6%
GFP+ on day 3 cells and 44±8% on day 13 cells; data not shown).
Thus, both R5X4 and R5 Envs are highly dependent on CCR5 expres-
sion levels, although R5 JRFL is more efﬁcient at exploiting limiting
levels than R5X4 Envs (Fig. 5A).
In contrast to CCR5, CXCR4 levels typically decreased somewhat
from day 3 to day 13, and this was associated with a modest decrease
in the percentage of cells infected via CXCR4 for the R5X4 viruses
tested as well as the X4 strain Tybe (Fig. 5B).Coreceptor-dependent R5X4 entry following lentiviral vector CCR5
over-expression
Although 10 days in culture with IL-2 upregulated CCR5 levels and
modulated coreceptor utilization, we considered the possibility that
the extended period in vitro could also affect other factors that impact
infection despite the lack of changes in VSV-G pseudotype infection.
For that reason, we used a second approach to upregulate CCR5. CD4+
lymphocytes were transduced after 3 days of PHA stimulation with
a lentiviral vector expressing CCR5 or a mutated version of the
coreceptor that is not expressed on the cell surface. CCR5 levels on
transduced cells were measured by FACS, and cells were infected with
prototype R5X4 Env luciferase viruses in the presence or absence
of AMD3100 to block CXCR4. Transduction with the CCR5 vector
increased the proportion of CCR5+ cells to 18–70% of CD4+
lymphocytes compared with 1–19% of cells transduced with a control
vector (Fig. 6), and the MFI of CCR5-positive cells increased as well
(fold increase of 2.9±0.9; data not shown). CCR5 over-expression
leads to a marked increase in entry mediated by CCR5 for R5X4
pseudotypes R3A and DH12 compared to control vector-transduced
cells (Fig. 6). In contrast, entry mediated by CCR5 increased only
marginally for strain 89.6. CCR5 transduction had no impact on the
MFI of CD4 or CXCR4 expression and did not impact infection by
the X4 virus Tybe (data not shown). Results from the lentiviral
vector CCR5 over-expression studies are similar to those following
stimulation-induced upregulation (Fig. 4), supporting the notion that
entry as measured here reﬂects changes in coreceptor expression and
not other features of the cell condition that might modulate infection.
Spectrum of CCR5 use on CD4+ lymphocytes by R5X4 HIV-1 correlates
with the use of low levels of CCR5 on 293 Afﬁnoﬁle cells
Increasing CCR5 expression on CD4+ lymphocytes increased the
proportion of infectionmediated by CCR5 for R5X4 viruses, suggesting
that inefﬁcient use of endogenous CCR5 might be linked to sensitivity
to coreceptor expression levels. To further address the interplay
between CCR5 expression and R5X4 infection, we used 293 Afﬁnoﬁle
cells, a cell line in which expression of CD4 and CCR5 can be regulated
precisely and independently by minocycline and ponasterone, respec-
tively (Johnston et al., 2009; Lassen et al., 2009). The number of CD4
and CCR5 antibody binding sites (ABS) per cell can be determined for
each inducer combination using quantitative FACS analysis. Induction
of Afﬁnoﬁle cells resulted in CD4 expression levels that ranged from
3000 to 200,000 ABS per cell and CCR5 levels from 1000 to 50,000 ABS
per cell. Importantly, these levels encompass the physiologically rele-
vant range of CD4 and CCR5 levels reported on stimulated CD4+
lymphocytes of 65,000–100,000 and 500–7000 molecules per cell,
respectively (Lee et al., 1999b). Therefore, we chose to examine the
sensitivity of R5X4 HIV-1 infection to CCR5 expression levels in
Afﬁnoﬁle indicator cells by analyzing the effect of varying CCR5
density in the presence of physiologically relevant CD4 expression
levels (∼83,000 molecules/cell). Cells were maintained with a stable
concentration of CD4 inducer and different concentrations of CCR5
inducer, and infected with luciferase pseudotype viruses at the same
time that receptor expression levels were conﬁrmed by FACS.
Luciferase levels produced at each CCR5 density were normalized to
luciferase activity in cells with the highest density of CCR5.
As shown in Fig. 7A, at a stable level of CD4 expression, luciferase
virus infection was reduced for all R5X4 viruses as CCR5 density
decreased. However, there were marked differences in the response
to declining CCR5 levels. R5X4 Envs C2-16 and NR10 were least
affected by declining CCR5 expression, showing 60 to 80% of maximal
infection even at the lowest CCR5 density. A second group of R5X4
viruses, R3A, DR17 and DH12, were more signiﬁcantly impaired
by low CCR5 expression, achieving 35–45% of maximal infection at
the lowest CCR5 expression tested. 89.6 was the R5X4 virus most
Fig. 6. Lentiviral over-expression of CCR5 increases the proportion of R5X4 entry
mediated by CCR5 on CD4+ lymphocytes. CD4+ lymphocytes were stimulated with
PHA for 3 days, transduced with either control or CCR5-expressing lentiviruses, and
maintained in the presence of IL-2. Two days post-transduction, cells were pretreated
for 1 h with CXCR4 blocker AMD3100 and infected with HIV-1 luciferase pseudotypes
in the continued presence of blocker. Infection was determined by luciferase activity in
cell lysates four days later. The results are shown as the proportion of CD4+
lymphocyte infectionmediated through CCR5 for R3A (A), DH12 (B) and 89.6 (C) on the
Y-axis, plotted against the percentage of CD4+ lymphocytes that express CCR5 after
transduction with a control or CCR5 expression vectors. Data are from three
independent experiments using cells from different donors.
Fig. 7. Efﬁciency of CCR5 use on Afﬁnoﬁle cells correlates with CCR5 use on CD4+
lymphocytes by R5X4 HIV-1. Afﬁnoﬁle cells were induced to express a ﬁxed level of CD4
(83,000 antibody binding sites (ABS)/cell) and varying levels of CCR5, then infected
with HIV-1 luciferase pseudotypes in the presence of AMD3100 to block endogenous
CXCR4. Infection was quantiﬁed 4 days later by luciferase activity in cell lysates. The
results are shown as the luciferase levels at each CCR5 density normalized to infection
levels on cells expressing the maximum density of CCR5 (A). The relationship between
normalized infection of Afﬁnoﬁle cells expressing the lowest density of CCR5 and the
proportion of total CD4+ lymphocyte infection that is mediated by CCR5 for each R5X4
Env pseudotype is also shown (B).
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CCR5 expression reached only 25% of its maximal level of infection
(Fig. 7A). Thus, R5X4 HIV-1 display a spectrum in their ability to use
diminishing levels of CCR5 on Afﬁnoﬁle cells in the presence of CD4
levels approximating those on primary CD4+ T cells.
We then asked if there was an association between R5X4 use of
lymphocyte CCR5 and entry into Afﬁnoﬁle cells expressing CCR5 at
the lowest density (Fig. 7A). Overall, there was a strong correlation for
R5X4 HIV-1 between the proportion of CD4+ lymphocyte entry
mediated by CCR5 and the ability to infect Afﬁnoﬁle cells expressing
diminishing levels of CCR5 (Fig. 7B). C2-16 and NR10 used CCR5 on
lymphocytes more efﬁciently than other R5X4 viruses and were least
sensitive to decreasing levels of CCR5 on the Afﬁnoﬁle cells. Lym-
phocyte CCR5 use was lowest for 89.6 and infection of Afﬁnoﬁle cells
wasmost impaired by decreasing CCR5 levels for this virus. DR17, R3A
and DH12 showed an intermediate phenotype in both lymphocyte
142 L.M. Loftin et al. / Virology 402 (2010) 135–148CCR5 use and infection of Afﬁnoﬁle cells expressing low levels of
CCR5. These results conﬁrm that there is biological heterogeneity
among R5X4 HIV-1, and suggest that strains with marginal CCR5 use
on lymphocytes are unable to effectively scavenge for CCR5 when it is
expressed at low density.
Relationship between V3 sequences and CD4+ lymphocyte coreceptor
preference
The V3 region is a major determinant of coreceptor use, and
position-speciﬁc scoring matrix (PSSM) algorithms based on varia-
tions in this domain are frequently used to predict viral phenotype.
Two widely used algorithms are based on viruses phenotyped by
syncytia induction in CXCR4/CD4+ cell lines (SI/NSI PSSM) or on
coreceptor use in indicator cells (X4/R5 PSSM), which are highly
related although not completely concordant features (Jensen et al.,
2003). However, such algorithms are typically less able to identify
dual-tropic R5X4 than single coreceptor R5 and X4 variants, nor have
they been applied to selective use of primary cell coreceptors. There-
fore, we applied the PSSM algorithms to V3 sequences from Envs
in our panel to determine whether primary CD4+ T cell coreceptor
usage among R5X4 HIV-1 might be associated with sequences in V3
(Table 1). Strikingly, we found that, for these R5X4 variants, pre-
diction of an NSI phenotype based on V3 sequence was associated
with relatively more efﬁcient use of lymphocyte CCR5. Conversely,
R5X4 viruses with more restricted entry through lymphocyte CCR5
were predicted to be SI. Thus, while unable to identify these R5X4
strains as a group, the SI/NSI algorithm appears to discriminate
among R5X4 strains and predict relative efﬁciency of lymphocyte
CCR5 use based on V3 determinants. In contrast, there was no link
between primary lymphocyte coreceptor usage and predicted
coreceptor phenotype based on V3 sequences using the X4/R5
coreceptor prediction algorithm. Interestingly, most of these R5X4
Envs were predicted to be R5 by the X4/R5 PSSM matrix, which
differed from the SI/NSI algorithm results. Thus, while the V3-based
PSSM is an incomplete predictor of coreceptor use for R5X4 strains, it
does appear to predict the relative coreceptor preference on
lymphocytes seen in this study. This result also suggests that elements
within V3 contribute to regulation of coreceptor use by R5X4 viruses
on lymphocytes.
Impaired CCR5 use on CD4+ lymphocytes by 89.6 is reversed by an
R306S mutation within the V3 region that enhances CCR5 interactions
While CCR5 use on CD4+ lymphocytes by R5X4 envelopes was
bolstered by increasing CCR5 expression, this measure had little effect
on lymphocyte CCR5 use by 89.6. Therefore, for this virus we wished
to address the Env side of the Env–CCR5 interaction, by determining ifTable 1
V3 sequence alignment and PSSMa viral phenotype prediction.
a Position-speciﬁc scoring matrix (Jensen et al., 2003).
b Percentage of total primary lymphocyte entry in the presence of CXCR4 blocking.
c Predicted SI phenotype based on SI/NSI PSSM algorithm; 0=NSI, 1=SI.
d Predicted coreceptor phenotype based on X4R5 PSSM algorithm; 0=R5, 1=X4 or R5Xspeciﬁc changes within V3 might alter the efﬁciency of CCR5 use and
affect lymphocyte entry. The presence of positively charged amino
acids at positions 11 and 24 or 25within the V3 loop is associatedwith
CXCR4 use (Cardozo et al., 2007; Xiao et al., 1998), and 89.6 exhibits a
positively charged arginine in both the 11 and 24 positions. In a recent
study of brain derived R5X4 envelopes, the efﬁciency of CCR5 and
CXCR4 use on primary cells was linked to the presence of a serine or
arginine, respectively, at position 11 of V3, corresponding to residue
306 of the Env glycoprotein (Gray et al., 2009). Another study
attempted to derive variants of 89.6 resistant to CXCR4 inhibitors on
cell lines expressing both coreceptors and identiﬁed a change from
arginine to serine at the same residue (Maeda et al., 2008).
We therefore speculated that the amino acid at position 306
within Env might be involved in determining the efﬁciency of 89.6
CCR5 interactions, and that it might thus regulate the ability or
inability of 89.6 to use CCR5 on lymphocytes. To test this notion, R306
in 89.6 was mutated to serine (89.6 R306S; Fig. 8A). In contrast to
89.6, the R5X4 Env with greatest lymphocyte CCR5 use, C2-16, has a
serine at position 11 in V3. Therefore, we also mutated the serine
at this position in C2-16 to arginine in order to assess the converse
effect (C2-16 S306R) (Fig. 8A). Both Envs remained R5X4 in U87/
CD4/coreceptor cells (data not shown).
We infected 293 Afﬁnoﬁles expressing a ﬁxed level of CD4 and
varying levels of CCR5 to test the effect of the Env mutations on the
efﬁciency of CCR5 use in that system. As noted earlier, infection by
89.6 decreased markedly as CCR5 density on Afﬁnoﬁles dropped from
maximal to minimal levels. Replacing the arginine at position 306
with serine resulted in a two-fold enhancement of entry at the lowest
CCR5 levels, reaching a relative efﬁciency of entry at low compared
to high CCR5 approximately that for C2-16 (Fig. 8B). In contrast, the
C2-16 S306R mutation had some effect on entry efﬁciency at inter-
mediate CCR5 levels, but not at the lowest CCR5 density; which most
closely mimics those on primary CD4+ lymphocytes (Fig. 8B).
Next, coreceptor use on primary CD4+ T cells by wild-type
and mutant 89.6 and C2-16 was determined by infecting CD4+
lymphocytes with luciferase viruses bearing each envelope in the
absence or presence of coreceptor antagonists. As shown in Fig. 8C, con-
verting arginine to serine at position 306 in Env dramatically enhanced
theuse of lymphocyte CCR5 for 89.6. In fact, 89.6R306S showedamarked
preference for infecting CD4+ lymphocytes using CCR5, in contrast to
wild-type 89.6, which was essentially restricted to CXCR4 for entry into
these cells. Unlike 89.6, CCR5 use on CD4+ lymphocytes by strain C2-16
was not affected by the converse S306R mutation (Fig. 8C).
Thus, replacing the positively charged arginine with serine at
residue 306 in the 89.6 Env increased the efﬁciency of CCR5 use,
and resulted in preferential infection of CD4+ lymphocytes through
CCR5, reversing its otherwise strict dependence on CXCR4 in those4.
Fig. 8. Arginine at position 11within the V3 region inﬂuences the efﬁciency of CCR5use by 89.6 and coreceptor preferenceon CD4+lymphocytes. The amino acids of envelopeV3 regions of
89.6 and C2-16 are shown, alongwith the 89.6 R306S and C2-16 S306Rmutations, which correspond to position 11 of theV3 domain (A). Afﬁnoﬁle cells expressing a ﬁxed level of CD4 and
differing levels ofCCR5were infectedwithwild-type andmutant89.6andC2-16 luciferase pseudotypeviruses. The results are shownas the luciferase levels at eachCCR5density normalized
to infection levels on cells expressing themaximumdensity of CCR5 (B). PHA-stimulatedCD4+lymphocyteswere infectedwithwild-type andmutant89.6andC2-16 luciferase pseudotype
viruses in the presence or absence of AMD3100, Maraviroc or a combination of both inhibitors. The results are presented as the RLUsmeasured from cell lysates 4 days after infection (C).
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determinant for all R5X4 viruses since converting serine to arginine
at that residue did not notably impact the efﬁciency of CCR5 use or
coreceptor preference on primary lymphocytes by the C2-16 Env,
indicating that other context-dependent factors are involved as
well.
Discussion
Coreceptor use and target cell tropism are important determi-
nants of HIV-1 transmission and pathogenesis. In previous studies of
primary cell tropism and coreceptor use by prototype R5X4 HIV-1
strains, we found that these viruses could use CCR5 and CXCR4 to
infect macrophages, but in CD4+ lymphocytes, CXCR4 was the
predominant entry pathway while CCR5 was used poorly, if at all.
Here we sought to determine, employing a variety of dual-tropic
isolates from disparate sources that would represent a broad
spectrum of phenotypes, whether and how R5X4 strains might
vary in their ability to use CCR5 on lymphocytes, and what factors
were responsible for determining the use of this pathway. We found
limited CCR5-mediated infection of CD4+ T cells by the R5X4
strains tested, which did not substantially contribute to overall
infection levels when CXCR4 was available. We did ﬁnd, however,
that a spectrum existed among the R5X4 variants in the extent to
which lymphocyte CCR5 could be used if CXCR4 was not available.
We also found that lymphocyte CCR5 use by R5X4 HIV-1 was
restricted primarily by the low CCR5 expression levels on CD4+ T
cells combined with inefﬁcient interactions between the R5X4envelopes and CCR5. Thus, we conclude that the spectrum of
lymphocyte CCR5 use by R5X4 viruses is determined by the
efﬁciency of Env–CCR5 interactions.
Even for R5X4 viruses with relatively greater lymphocyte CCR5
use, blocking this pathway had no impact on CD4+ T cell infection, as
entry through CXCR4 alone was equivalent to infection when both
coreceptors were available. CXCR4 is expressed on the majority of
peripheral blood CD4+ lymphocytes, whereas CCR5 is expressed on
a smaller subset of cells (Lee et al., 1999b; Ostrowski et al., 1998; van
Rij et al., 2000; Wu et al., 1997). Most cells that are CCR5+ also
express CXCR4; so blocking CCR5 may have little net effect on
infection because entry can still occur through CXCR4. Conversely,
since many CXCR4+ lymphocytes do not express CCR5, entry in the
presence of CXCR4 blockers should be representative of the subset of
cells that express CCR5. Nevertheless, the level of CCR5-mediated
lymphocyte infection by R5X4 viruses varied and was determined by
the efﬁciency of CCR5 use, as indicated by lower sensitivity to CCR5
blocking agents and a better ability to use low levels of CCR5 on
indicator cells. The density of CCR5 expressed on individual CD4+
lymphocytes varies within the CCR5+ population (Reynes et al.,
2000) and, thus, while potential CCR5-mediated infection is deter-
mined by the proportion of cells that express CCR5, actual CCR5
use by a speciﬁc R5X4 virus is also regulated by the threshold of CCR5
it requires for infection. Thus, the differences in CCR5/Env inter-
actions identiﬁed among the R5X4 strains here, which regulate
the threshold of CCR5 required for entry, are the principal factors
underlying differences in CCR5-mediated target cell availability for
each isolate.
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use among R5X4 variants is due to the efﬁciency with which Env
engages CCR5. Multiple steps are involved in coreceptor-dependent
entry and infection, including Env–chemokine receptor binding,
which is inﬂuenced by the amino acids within the V3 loop (Cormier
et al., 2001; Platt et al., 2001; Sakaida et al., 1998; Wu et al., 1996).
While the presence of arginine at position 11 within the V3 loop
of 89.6 was associated with inefﬁcient CCR5 use and poor CCR5-
mediated primary lymphocyte infection, this amino acid in the con-
text of the C2-16 region had no impact on CCR5 use. Characterization
of R5X4 clones from subtype D strains on dual coreceptor expressing
cell lines revealed thatmore efﬁcient CCR5 usewas associatedwith V3
sequences that were more “R5 like”, while “X4 like” V3 sequences
were linked to less efﬁcient CCR5 use (Huang et al., 2007). The 89.6 V3
region has hallmarks of CXCR4 use such as a high net positive charge
and basic amino acids at both positions 11 and 24, determinants that
are lacking in C2-16, and CCR5 use by 89.6 and C2-16 are similar to the
subtype D Envs with more “X4 like” or “R5 like” V3 sequences,
respectively. This result is consistent with recent studies indicating
a critical role for this region within the V3 loop in determining
coreceptor utilization by other R5X4 isolates (Gray et al., 2009; Nolan
et al., 2008), although our data indicate that amino acid 11 is not a
critical determinant for all R5X4 isolates. Thus, our ﬁndings suggest
that different R5X4 viruses interact with this coreceptor in distinct
ways. Of note, this residue was also shown to regulate the relative
dependence of R5X4 HIV-1 Envs on speciﬁc regions within CCR5 and
CXCR4, particularly the N-terminal domain (Gray et al., 2009), sug-
gesting that in addition to overall efﬁciency, it can also affect the
manner in which Env–coreceptor interactions occur.
Extending the role of V3, we also evaluated the relationship to
coreceptor use predicted by PSSM algorithms, which have been
developed to take into account multiple V3 sequence factors in order
to predict viral phenotype (Jensen et al., 2003). PSSM predictive
algorithms are not highly accurate for distinguishing R5X4 from single
coreceptor-tropic viruses, but we found that among R5X4 variants the
SI/NSI matrix showed a strong correlation between “NSI-like” char-
acteristics and greater lymphocyte CCR5 use, and “SI-like” and poorer
lymphocyte CCR5 use. In contrast, the X4/R5 predictive matrix, based
on coreceptor use in indicator cell lines, did not distinguish between
R5X4 strains with greater or lesser lymphocyte CCR5 use. These
results further support the role of V3 in determining coreceptor
preference in the context of primary cells and, in addition, further
emphasize the limitations of indicator cells in predicting primary cell
coreceptor use. Future studies will be needed to characterize the
strains for which phenotype predictions differ between the scoring
matrices, and determine whether these Envs may exhibit other dis-
tinguishing features in their interactions with primary cells.
The R5X4 strains in this report exhibited a spectrum in their
efﬁciency of lymphocyte CCR5 use, but none preferentially infected
CD4+ T cells using this coreceptor. On one hand, this is not surprising
given the difference in number of cells positive for each coreceptor. On
the other hand, R5X4 strains emerge in vivo fromR5 strains inmemory
lymphocytes that express CCR5 and CXCR4, while later in infection,
R5X4 along with X4 viruses are found mostly in the CCR5−/CXCR4+
naive subset (van Rij et al., 2000). Thus, it seems likely that some R5X4
strains would use CCR5 as the predominant coreceptor to infect CD4+
T cells. The fact that the R306S mutation in 89.6 changes coreceptor
preference on lymphocytes from CXCR4 to CCR5 indicates that this
type of R5X4 Env can exist and that only minor changes may be
required to shift between these twophenotypes. Perhaps R5X4 viruses
that predominately use CCR5 to infect lymphocytes emerge but then
rapidly disappear from the viral quasispecies. Alternatively, evolution
of R5X4 strainsmight never transit through a phasewhere CCR5 use is
dominant. In a study of in vitro-derived R5X4 switch variants, the
earliest CXCR4-using Envs were more sensitive to CCR5 antagonists
and less efﬁcient at using CCR5 for entry when compared to theparental R5 virus (Pastore et al., 2004), and the mutations conferring
CXCR4 use were detrimental except when introduced with compen-
satory changes elsewhere in the envelope (Pastore et al., 2006). In vivo,
R5 strains showed reduced ability to infect CCR5-low cells prior to the
emergence of R5X4 viruses (Coetzer et al., 2008). Thus, CXCR4 usemay
only emerge after compensatory mutations occur that have the effect
of decreasing CCR5 use, suggesting that R5X4 evolution may not
involve a phase of predominate lymphocyte CCR5 use.
R5 viruses are responsible for themajority of newHIV-1 infections,
but it is still not clear why only this type of strain is able to transmit or
successfully establish new infections. R5 strains are typically more
macrophage-tropic than X4 variants, and CCR5-dependent macro-
phage tropismwas classically proposed as a possible reason (Liu et al.,
1996; van't Wout et al., 1994; Zhu et al., 1993). However, R5X4 strains
also use CCR5 to infect primary macrophages, yet this strain is rarely
transmitted (Liu et al., 1996; van't Wout et al., 1994; Yi et al., 2005).
Furthermore, recent studies using transmission pair isolates obtained
near the time of transmission enabling donor/recipient comparison,
or PCR ampliﬁcation and phylogenetic reconstruction of the success-
fully transmitted virus, reveal that these founder viruses are re-
stricted to CCR5 and readily infect lymphocytes but typically infect
macrophages inefﬁciently and/or no better than the donor variants
(Isaacman-Beck et al., 2009; Keele et al., 2008; Salazar-Gonzalez et al.,
2009). The fact that R5X4 variants generally use lymphocyte CCR5
poorly relative to R5 viruses raises the possibility that these strains do
not establish infections in recipients because use of CCR5 on lym-
phocytes is the critical determinant of transmission. Alternatively, it is
possible that neither R5X4 nor X4 strains efﬁciently transmit because
CXCR4 use is selected against during transmission or establishment of
new infections in recipients (Cornelissen et al., 1995).
The limited CCR5-mediated infection of lymphocytes by R5X4HIV-1
raise questions of whether CCR5 use by R5X4 viruses has any impact on
viral pathogenesis. Although rare, R5X4 strains have been transmitted
and theseviruseswere able toestablish infection in recipients (Meissner
et al., 2004; Yu et al., 1998). Given the importance of CCR5 use in
transmission, these viruses might be expected to utilize lymphocyte
CCR5more efﬁciently than R5X4 viruses that arise later. Strain R3Awas
obtained from an unusual R5X4 acute infection (Meissner et al., 2004),
but R3A was not among the R5X4 Envs with more efﬁcient lymphocyte
CCR5 use. It is interesting to note, and somewhat unexpected, that the
two variants with greatest relative efﬁciency in lymphocyte CCR5 use
were NR10 from a late-stage patient and C2-16 from a CCR5-null
subject, neither of which are situations inwhich onemight expectmore
efﬁcient lymphocyte CCR5 use. Macrophage infection is thought to be
the major source of virus in tissue, a critical component of neuropatho-
genesis, and responsible for sustaining virus replication at very late
stages of disease (Igarashi et al., 2001; Koenig et al., 1986; Schuitemaker
et al., 1992). Prototype and some primary R5X4 strains readily infect
macrophages usingCCR5,whichmaybeexplainedby the higher density
of CCR5 expressed on these cells compared with primary CD4+
lymphocytes (Lee et al., 1999b; Yi et al., 2005). However, the use of
this coreceptor may be dispensable since CXCR4 also serves as a viable
coreceptor for R5X4 entry into these cells (Yi et al., 2005). Thus, it
remains to be determined how the efﬁciency of lymphocyte CCR5 use
among R5X4 variants is linked to speciﬁc aspects of pathogenesis. In
addition, while X4 use is common in subtype B HIV-1, it is less frequent
among subtype C strains and, furthermore, the factors that regulate
coreceptor interactions may differ for different subtypes (Lynch et al.,
2009), so further studies will be needed to determine the extent to
which these ﬁndings apply to other subtypes.
In summary, this study conﬁrms with a panel of primary and
prototype R5X4 HIV-1 variants that these strains are highly skewed
towards CXCR4 use for entry into CD4+ T cells. However, there does
exist a range among the isolates in the relative ability to use CCR5 on
primary lymphocytes, although we did not identify an evident rela-
tionship between relative lymphocyte coreceptor use and the clinical
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lymphocyte CCR5 by R5X4 variants was linked to greater efﬁciency in
CCR5 interactions, based on antibody and small molecule antagonist
blocking studies. Furthermore, the barrier to CCR5 use could be over-
come by CCR5 over-expression in lymphocytes for most of the R5X4
isolates or, if not, by mutating Env to enhance coreceptor interaction
efﬁciency. These results indicate that efﬁciency of the Env–CCR5
interactions combined with low lymphocyte CCR5 expression
together determine the extent of restriction to R5X4 entry through
this pathway, although additional obstacles to primary cell coreceptor
use may still exist. Better understanding of the viral and cellular
factors that control coreceptor use by HIV-1 strains is critical to
understanding the impact of viral evolution on target cell tropism.
Materials and methods
Cells
CD4+ lymphocytes were isolated by negative selection from whole
blood (Stem Cell Technologies, Vancouver, BC, Canada). Puriﬁed
lymphocytes were maintained at 106 cells/ml and stimulated for
3 days with 5 µg/ml of phytohemagglutinin (PHA; MP Biomedical,
Solon,OH) or in 24well plates coatedwith5 µg/mlof anti-CD3 (OKT3; a
gift fromM.Betts, U. of Pa.) and anti-CD28 (clone28.2; BeckmanCoulter,
Fullerton, CA) antibodies. Cells were then either infected and main-
tained thereafter in IL-2, or cultured for 10 days in IL-2 (300 U/ml;
Proleukin, Novartis, Basel, Switzerland) to upregulate CCR5 prior to
infection. 293 Afﬁnoﬁle cells that express CCR5 and CD4 under
independent regulation were maintained in blasticidin, G418, hygro-
mycin and zeocin (Invitrogen, Carlsbad, CA) (Johnston et al., 2009;
Lassen et al., 2009). U87/CD4, U87/CD4/CXCR4 and U87/CD4/CCR5
cells were obtained from D. Littman (NYU) through the NIH AIDS
Research and Reference Reagent Program (Björndal et al., 1997) and
were maintained in selective media containing 1 µg/ml of puromycin
(MPBiomedical, Solon, OH) or 300 µg/ml of G418 (Invitrogen, Carlsbad,
CA) for selection of CD4 or CCR5 and CXCR4 respectively.
HIV-1 Env clones
HIV-1 R5X4 prototypes 89.6 and DH12 and primary isolate NR Env
clones were derived from patients with advanced disease and have
been previously described (Collman et al., 1992; Ray et al., 2007;
Shibata et al., 1995). Env clone R3A was derived from an acute
seroconverter found to harbor R5X4 variants and has been described
previously (Meissner et al., 2004; Yu et al., 1998). R5X4 variants C2
and DR were obtained from two HIV-infected CCR5-null individuals
homozygous for the Δ32 allele (Gray et al., 2006). The X4 isolate Tybe
and R5 strains JRFL and Bal have also been described previously
(Gartner et al., 1986; Koyanagi et al., 1987; Yi et al., 2003a). Prototype
89.6, R3A, JRFL and Tybe Envs alongwith NR Envswere subcloned into
the expression vector pCAGGS (Niwa et al., 1991) using standard
methods. The expression vectors used to subclone the remaining
vectors have been previously described (Helseth et al., 1990; Kim et
al., 2001). 89.6 and C2-16 envelope clones with mutations at position
11 within the V3 loop were generated using a Quick Change XL
mutagenesis kit (Stratagene, La Jolla, CA). NR Env clones were a gift
from R. Doms (U. of Pa.), R3A was obtained from J. Hoxie (U. of Pa.)
and kindly provided by L. Su (UNC-Chapel Hill), and JRFL, DH12 and
Bal Env clones were generously provided by M. Cho (Case Western
Reserve).
Pseudotype virus production
HIV-1 Env luciferase pseudotype viruses were generated by
cotransfecting a plasmid that expressed HIV-1 structural proteins
(pCMVΔP1ΔenvpA), a plasmid that expressed the packaged luciferasereporter (pHIV-1 luc), and an HIV-1 or VSV-G Env plasmid. Plasmids
were cotransfected into 293 cells using Fugene transfection reagent
(Roche, Palo Alto, CA) at ratios of 1:3:1 as previously described
(Sterjovski et al., 2007; Yang et al., 2004). GFP reporter viruses were
created by cotransfection of structural gene plasmid pHp1, GFP
reporter plasmid pHRET-GFP, the tat expression plasmid pCep4-tat,
and a plasmid expressing an HIV-1 or VSV-G Env. Plasmids were
cotransfected into 293 cells at a ratio of 10:10:1:10 as previously
described (Chang et al., 1999). The CCR5 lentiviral expression vector
pNL-CCR5 was created from pNL-CD4 by digestion with NotI and XhoI
to remove CD4, and the CCR5 gene was ampliﬁed (sense primer 5′-
TAG TGC TGT TAA CTT GCT CAA TGC-3′ and antisense 5′-GAT CAA GGA
TAT CTT GTC TTC-3′) and subcloned into the NotI and XhoI sites. CCR5
transduction vectors were produced by cotransfecting pRev, pNL-
CCR5 and pVSV-G into 293 cells at a ratio of 1:2:1.
HIV-1 Env pseudotype viruses and lentiviral expression vectors
were harvested 48 h after transfection, clariﬁed by centrifugation
at 250 ×g, then stored in 5% sucrose at −80 °C until use. Plasmids
pCMVΔP1ΔenvpA (Parolin et al., 1996) and pHIV-1-luc (Yang et al.,
2004) were generously provided by J. Sodroski (Harvard University),
and pNL-CD4 (Tokunaga et al., 2001) was kindly provided by B.
Cullen (Duke University). Plasmid pHRET-GFP (Lin et al., 2002) was
provided by P. Corbeau (Hôpital Saint Eloi) and pHp1 and pCep4-tat
(Chang et al., 1999) were gifts from J. Zucali (University of Florida)
obtained through the NIH AIDS Research and Reference Reagent
Program.
CCR5 over-expression in CD4+ lymphocytes
PHA-stimulated CD4+ lymphocytes were pelleted (250 ×g at
25 °C for 5 min) and resuspended at 2×106 cells per ml in media
containing 8 µg/ml of Polybrene. Cells were then transduced using
200 µl of CCR5 expression vector pNL-CCR5, spin inoculated for 2 h as
described (O'Doherty et al., 2000), then incubated in the presence
of 10 U/ml of IL-2 at 37 °C and 5% CO2 for 72 h. After this period,
coreceptor expression was analyzed by FACS and cells were used for
infection.
Infection of cell lines and CD4+ lymphocytes
U87 cells were plated in 96 well plates at 1.5×104 cells per well
one day prior to infection, infected by spin inoculation at 1200°g for
2 hwith HIV-1 pseudotype viruses using 5 ng of p24 antigen per virus,
and cultured at 37 °C and 5% CO2 for three days. For blocking studies,
U87/CD4/CCR5 cells were pretreated for 1 h and then infected in the
presence of 10 µg/ml of CCR5 mAb or serial dilutions of the CCR5
small molecule antagonists. Luciferase activity was measured by
lysing cells in PBS containing 0.1% Triton X-100, combining cell lysate
1:1 with luciferase assay substrate (Luciferase Assay System;
Promega, Madison, WI) and measuring luciferase relative light units
(RLUs) using a Dynex technologies microtiter plate luminometer.
Monoclonal antibodies 2D7, 45531 and CTC8 were obtained from the
NIH AIDS Research and Reference Reagent Program, and mAb MC-1
(Blanpain et al., 2002)was a gift fromM.Mack (University ofMunich).
The CCR5 blocker M657 (Finke et al., 2000) was a gift from M. Miller
(Merck, W. Point, P.A.), and Maraviroc (Dorr et al., 2005) (Pﬁzer Inc.,
New York City, NY) was obtained through the NIH AIDS Research and
Reference Reagent Program.
For infection of primary cells, PHA or CD3/CD28-stimulated CD4+
lymphocytes were added to 96 well plates at 2×105 cells per well.
Cells were pretreated for 1 h with saturating concentrations of CCR5
antagonists M657 (5 µg/ml) or Maraviroc (2 µM), the CXCR4 antag-
onist AMD3100 (5 µg/ml; Sigma-Aldrich, St. Louis, MO) or a combina-
tion of CCR5 and CXCR4 blockers. Following pretreatment, CD4+
lymphocytes were infected in the presence of the inhibitors using
an equal volume or 10 ng of p24 antigen of each virus for PHA or
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infected by spin inoculation at 1200 ×g for 2 h, and then cultured at
37 °C and 5% CO2 in the presence of IL-2 for 3 days. Infection was
measured by luciferase activity in the cell lysate as previously de-
scribed, or by FACS analysis of GFP expression.
Infection of 293 Afﬁnoﬁles has been described in detail previously
(Johnston et al., 2009; Lassen et al., 2009). Brieﬂy, cells were plated at
1.5×104 cells per well in 96 well plates in media containing 2%
dialyzed FBS. Cells were allowed to adhere for two days, then media
was removed and replaced with media containing a ﬁxed concentra-
tion of the CD4-inducing reagent Minocycline (0.625 ng/ml) and
varying concentrations of the CCR5 inducer Ponasterone (0–2 µM).
After an overnight incubation, cells were pretreated for at least 1 h
with 1 µg/ml of AMD3100 to block CXCR4 in media containing 10%
dialyzed FBS, then infected by spin inoculation using 1 ng of p24
antigen of each luciferase pseudotype virus. Infected cells were cul-
tured for 4 days at 37 °C and 5% CO2, then luciferase activity was
measured as described. FACS analysis of CCR5 and CD4 expressionwas
carried out the day of infection on cells that were plated in 6 well
plates and maintained in an identical manner.FACS analysis of CD4, CCR5, CXCR4 and GFP expression
CD4+ lymphocytes were pelleted (250 ×g for 5 min), washed
with FACS buffer (PBS containing 1% fetal bovine serum and 0.1%
NaN3), resuspended in 50 µl of FACS buffer and stained with 1 µl of
mAbs to CD4 (clone RPAT-4-Fluorescein isothiocyanate [FITC]-
conjugated), CCR5 (clone 2D7-phycoerythrin [PE]-conjugated), and
CXCR4 (clone 12G-PE-Cy5-conjugated) (all from BD Biosciences, San
Jose, CA). Fluorescence minus one controls as well as cells stained
with single antibodies was carried out in parallel. Cells were incubated
at room temperature in the dark for 30 min then washed and
resuspended in FACS buffer at 106 cells per ml. Cells were analyzed by
a FACS Calibur ﬂow cytometer (BD) using Cell Quest (BD) and FloJo
software (Tree Star Inc, Ashland, OR).
For CD4 and CCR5 quantiﬁcation on 293 Afﬁnoﬁles, cells were
detached by incubation for 10 min in PBS containing 2 mM EDTA,
pelleted, washed in FACS buffer then stainedwith the CCR5 PEmAb or
with CD4 PE mAb (clone S3.5-Invitrogen, Carlsbad, CA) as described
above. CD4 and CCR5 binding sites were quantiﬁed using FloJo Soft-
ware by comparing the average mean ﬂuorescence intensity of
stained cells to a standard curve created using PE-labeled beads with
four distinct, deﬁned quantities of ﬂuorophores (QuantiBrite Beads,
BD) as described (Davis et al., 1998). For detection of GFP expression
after CD4+ T cell infection by HIV-1 pseudotypes, cells were washed
and resuspended in FACS buffer as described 3 days post-infection
and analyzed for GFP ﬂuorescence using the FACS Calibur ﬂow cyto-
meter and FloJo software.Statistical analysis and PSSM matrix scoring
Statistical analysis was performed using GraphPad Prism 4 soft-
ware. The EC50 values for M657 and Maraviroc were determined
using a sigmoidal dose response equation. Correlations were derived
by linear regression analysis, and correlation coefﬁcients and p-values
were determined using a 2-tailed Pearson test.
The predicted viral phenotype of R5X4 Envs used in this study was
determined using the position-speciﬁc scoring matrix (PSSM)
program (http://indra.mullins.microbiol.washington.edu/webpssm/
). The PSSM algorithm compares amino acids at each position within
the V3 of submitted envelopes to the corresponding residues from a
database of Envs experimentally analyzed for coreceptor use (R5/X4
matrix) or viral isolates tested for T cell line synctium inducing ca-
pacity (SI/NSI matrix) as previously described (Jensen et al., 2003).Acknowledgments
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